Research

Macro partitioning

GLP-1 based therapies (Retatrutide, Ebenatide) cause significant muscle mass loss at higher doses, whereas lower doses or standard GLP-1 agonists preserve muscle mass better.

If you are using high-dose GLP-1 based therapies (like Retatrutide 8-12mg), be aware that you may lose more muscle than with lower doses or standard GLP-1s. This is a trade-off for greater fat loss. Prioritize protein intake and resistance training to protect your muscle mass, especially if you are older.

ModerateQualifiesMEDIUM confidence
Retatrutide at 8 and 12 mg significantly reduced body weight, total fat mass, and muscle mass at 36 weeks (p < 0.0001)... Ebenatide at 2 mg promoted weight loss... Body fat decreased at 24 weeks with preserved muscle mass. However, muscle mass declined slightly by 52 weeks.
Weena Joongpan et al. · Pharmacology Research & Perspectives · 2026

Why this rating

Based on only 2 recent RCTs, analyzed separately due to limited data.

Source

The Effects of <scp>SGLT</scp> 2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis

Weena Joongpan et al. · Pharmacology Research & Perspectives · 2026

DOI 10.1002/prp2.70232

Meta-analysis · 8 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →